ArticleJHLT open2025
Risk factors for lung transplant candidate waitlist removal in the era of the composite allocation score.
Article in JHLT open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Implementation of the composite allocation score (CAS) has improved, but not eliminated, waitlist mortality amongst lung transplant candidates. Identifying risk factors for clinical deterioration is important to stratify patients who may benefit from closer monitoring or increased support. We performed a UNOS registry-based study of lung transplant candidates listed between March 9, 2022 to March 8, 2024; analysis was stratified by listings before or after CAS implementation. Univariate and multivariate logistic regression analyses were performed to identify factors associated with waitlist removal for clinical decompensation or death. Traits associated with waitlist removal during the pre-CAS era were short stature, ECMO support at listing, and amount of supplemental oxygen. Following CAS implementation, ECMO support, low BMI, poor functional status, short stature, and ABO blood type O were significantly associated with waitlist removal. Close monitoring of patients with increased likelihood for waitlist removal, especially patients with multiple risk factors, may be appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.